RBMY2TP

Across TCGA pan-cancer cohorts, RBMY2TP RNA is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated RBMY2TP data layer.

The strongest signal is observed in thymoma (THYM), where higher RBMY2TP RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RBMY2TP expression acts as an unfavorable survival marker, although some lineages such as ESCA and READ show a favorable association.

THYM, BLCA, and LIHC are the cancer types where RBMY2TP RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	DFS	Tertile	All	0.123	0.825	<.001	99	view →
BLCA	OS	Tertile	All	0.069	0.688	<.001	54	view →
LIHC	OS	Tertile	II,III,IV	0.172	0.620	.003	45	view →
SKCM	DFS	Tertile	All	0.058	0.757	<.001	36	view →
LUSC	OS	Tertile	II,III,IV	0.100	0.780	<.001	36	view →
ESCA	OS	Tertile	III,IV	0.755	0.361	.048	6	view →
KIRC	OS	Tertile	All	0.453	0.664	.043	3	view →
READ	OS	Median	All	0.814	0.357	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

RBMY2TP–THYM (DFS)

Open the THYM breakdown →